TABLE 5.
Risk factors for reported side effects at 2-month review by univariate and multivariate models
| Variablea | OR (95% CI) for reported side effects | Adjusted OR (95% CI) for reported side effects |
|---|---|---|
| INH AUC0–24 quartile 1 | 1 | 1 |
| INH AUC0–24 quartile 2 | 1.26 (0.34–4.84) | 1.19 (0.29–4.87) |
| INH AUC0–24 quartile 3 | 1.88 (0.52–6.84) | 2.08 (0.54–8.07) |
| INH AUC0–24 quartile 4 | 7.11 (1.99–25.47) | 9.12 (2.28–36.55) |
| 10-yr increase in age | 1.09 (0.71–1.67) | 1.14 (0.68–1.92) |
| Previous isoniazid treatment | 1.54 (0.67–3.55) | 1.76 (0.63–4.97) |
| HIV-1 serostatus | 1.56 (0.64–3.80) | 1.12 (0.41–3.08) |
| Alcohol intake | 1.46 (0.63–3.41) | 1.92 (0.72–5.16) |
| Type 2 diabetes mellitus | 1.99 (0.26–14.17) | 1.67 (0.12–14.28) |
a
Abbreviations: INH, isoniazid; AUC0–24, area under the concentration-time curve from 0 to 24 h.